Table 3. Multivariate Cox regression analysis of the association of various clinicopathological features with overall survival (OS) and progression-free survival (PFS).
| Features | OS | PFS | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| * stage N1 vs. N0 | 3.960 (2.163-7.250) | <0.001 | 2.138 (1.044-4.379) | 0.038 |
| HPV status Positive vs. negative | 0.209 (0.065-0.673) | 0.009 | 0.306 (0.122-0.772) | 0.012 |
| PTOV1 High vs. Low | 2.806 (1.518-5.185) | 0.001 | 2.238 (1.271-3.941) | 0.005 |
| Hemoglobin ≥ 143.5 g/L vs. <143.5g/L | 0.593 (0.362-0.971) | 0.038 | ||
| Treatment method Comprehensive vs. Surgery | 1.987 (1.131-3.488) | 0.017 | ||
| **HPV-negative group PTOV1 High vs. Low | 2.943 (1.557-5.563) | 0.001 | 2.246 (1.250-4.034) | 0.007 |
| N stage N1 vs. N0 | 3.939 (2.151-7.212) | <0.001 | 2.139 (1.044-4.384) | 0.038 |
| Hemoglobin ≥ 143.5 g/L vs. <143.5g/L | 0.595 (0.363-0.974) | 0.039 | ||
| Treatment method Comprehensive vs. Surgery | 1.985 (1.127-3.498) | 0.018 | ||
| ***HPV/PTOV1 status | <0.001 | 0.004 | ||
| HPV+/PTOV1- | 1.000 | 1.000 | ||
| HPV+/PTOV1+ | 1.223 (0.111-13.521) | 0.870 | 2.294 (0.253-20.813) | 0.461 |
| HPV1-/PTOV1- | 2.472 (0.321-19.062) | 0.385 | 3.334 (0.438-25.388) | 0.245 |
| HPV-/PTOV1+ | 7.278 (0.998-53.073) | 0.050 | 7.449 (1.018-54.482) | 0.048 |
Abbreviations: LSCC, laryngeal Squamous cell carcinoma; PTOV1, prostate tumor overexpressed-1 (PTOV1); HPV, human papillary virus; HR, hazards ratio.
*
The clinicopathological features associated with the overall survival (OS) and progression-free survival (PFS);
**
The subgroup analysis of the clinicopathological features associated with the overall survival (OS) and progression-free survival (PFS) in the HPV negative subgroup;
***
The clinicopathological features associated with the overall survival (OS) and progression-free survival (PFS) when combined the HPV status and PTOV1 expression level